Actinium Pharmaceuticals (ATNM) AI Stock Analysis

• Market Cap: $43.36M
• Dividend Yield: N/A
• Average Volume (3M): 208.30K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.06
• Revenue Growth: 11.11%
• EPS Growth: 20.65%
• Country: US
• Employees: 31
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.16
• Shares Outstanding: 31,195,890
• 10 Day Avg. Volume: 380,172
• 30 Day Avg. Volume: 208,296
• PEG Ratio: 0.03
• Price to Book (P/B): 1.16
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.15
• Enterprise Value/Market Cap: -0.74
• Enterprise Value/Revenue: -355.82
• Enterprise Value/Gross Profit: 43.93
• Enterprise Value/Ebitda: 0.95
• 1Y Price Target: $6.00
• Price Target Upside: 361.54% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $1.50 ▲(15.38% Upside)

The score is primarily weighed down by weak financial performance—very low revenue, large ongoing losses, and sustained cash burn—partly offset by low leverage. Technicals are neutral-to-weak with the stock trading below key moving averages and only modest momentum. Valuation offers limited support given negative earnings and no dividend.

Positive Factors

Innovative Product Pipeline

The ARC platform represents a significant competitive advantage, potentially offering targeted cancer therapies that spare healthy tissue, which could lead to successful commercialization and partnerships.

Partnership Revenue Model

Actinium's strategy of partnering with larger firms for drug development and commercialization provides a pathway to revenue through upfront and milestone payments, reducing the financial burden of independent development.

Low Debt Levels

A low reliance on debt enhances financial stability and flexibility, allowing the company to focus on R&D and strategic partnerships without the pressure of high interest obligations.

Negative Factors

Negative Revenue Growth

Consistent revenue decline indicates challenges in product commercialization and market penetration, potentially limiting future growth and financial sustainability.

Negative Cash Flow

Persistent negative cash flow from operations suggests that the company is not generating sufficient internal funds, increasing reliance on external financing and posing risks to long-term viability.

Substantial Net Losses

Ongoing net losses highlight operational inefficiencies and high costs relative to revenue, which could hinder investment in R&D and delay the path to profitability.

Actinium Pharmaceuticals Business Overview & Revenue Model

Company Description

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.

How the Company Makes Money

Actinium Pharmaceuticals generates revenue through a combination of partnerships, licensing agreements, and potentially, future sales of its developed therapies. The company's revenue model primarily involves collaborations with larger pharmaceutical companies to co-develop and commercialize its proprietary therapies. These partnerships often include upfront payments, milestone payments, and royalties based on the successful development and commercialization of its drug candidates. Actinium's focus on advancing its pipeline through clinical trials also positions it to earn revenue from the eventual approval and sale of its therapeutic products. Additionally, the company may engage in research and development agreements with academic and research institutions to further its scientific initiatives.

Actinium Pharmaceuticals Financial Statement Overview

Summary

Actinium Pharmaceuticals faces significant financial challenges with declining revenues, substantial net losses, and negative cash flows. While the balance sheet shows low leverage, the company's ability to generate revenue and positive cash flows remains a key concern. Continued reliance on external financing poses risks if not managed carefully.

Income Statement

Actinium Pharmaceuticals shows a negative revenue growth trajectory with declining revenues over the years, zero revenue in the latest report, and consistent net losses. Profitability metrics, such as net profit margin, are negative due to significant operating losses and no gross profit, indicating high operational costs relative to revenue.

Balance Sheet

The company has a low debt-to-equity ratio, suggesting a low reliance on debt financing, which is positive. However, the persistent negative net income affects the return on equity (ROE), making it negative. The equity ratio is relatively stable, indicating a moderate level of equity funding compared to total assets.

Cash Flow

Operating cash flow is consistently negative, reflecting ongoing cash outflows from operations. The free cash flow is also negative, indicating that the company is not generating enough cash to cover its capital expenditures. Despite this, there is a significant reliance on financing activities to sustain operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	90.00K	0.00	81.00K	1.03M	1.14M	0.00
Gross Profit	-729.00K	-811.00K	81.00K	1.03M	620.00K	-447.00K
EBITDA	-33.78M	-37.43M	-51.13M	-33.41M	-24.25M	-21.77M
Net Income	-34.60M	-38.24M	-48.82M	-33.02M	-24.77M	-22.21M
Balance Sheet
Total Assets	56.15M	76.90M	81.44M	114.19M	80.39M	66.40M
Cash, Cash Equivalents and Short-Term Investments	53.39M	72.90M	76.68M	108.91M	77.83M	63.61M
Total Debt	1.14M	1.57M	2.11M	2.58M	310.00K	738.00K
Total Liabilities	42.37M	44.14M	45.07M	47.71M	6.84M	5.08M
Stockholders Equity	13.78M	32.76M	36.38M	66.48M	73.55M	61.32M
Cash Flow
Free Cash Flow	-25.04M	-33.08M	-47.49M	8.28M	-21.00M	-21.87M
Operating Cash Flow	-25.04M	-33.07M	-47.34M	8.64M	-20.87M	-21.62M
Investing Cash Flow	0.00	-11.00K	-153.00K	-366.00K	-133.00K	-253.00K
Financing Cash Flow	-217.00K	29.32M	14.87M	23.11M	35.22M	76.18M

Actinium Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATNM, the sentiment is Negative. The current price of 1.3 is below the 20-day moving average (MA) of 1.49, below the 50-day MA of 1.42, and below the 200-day MA of 1.53, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 38.54 is Neutral, neither overbought nor oversold. The STOCH value of 27.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATNM.

Actinium Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
UNCY	49 Neutral	$132.82M	-1.81	-102.47%	―	―	66.05%
GANX	46 Neutral	$88.85M	-3.35	-261.72%	―	―	42.29%
ATNM	45 Neutral	$43.36M	-1.17	-133.09%	―	11.11%	20.65%
IFRX	40 Underperform	$69.82M	-0.97	―	―	―	―

Actinium Pharmaceuticals Corporate Events

Actinium Pharmaceuticals Holds Annual Stockholders Meeting

On November 26, 2025, Actinium Pharmaceuticals held its annual meeting of stockholders, where Ajit S. Shetty and June S. Almenoff were re-elected as Class III directors for a term expiring in 2028. The meeting also saw the ratification of CBIZ as the independent public accounting firm for 2025 and approval of executive compensation-related proposals, reflecting continued shareholder support for the company’s governance and strategic direction.

The most recent analyst rating on (ATNM) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Actinium Pharmaceuticals stock, see the ATNM Stock Forecast page.